# Foresite Capital Management IV, LLC: Form 13F holdings

An institutional investment manager in WEST HOLLYWOOD, CA. SEC CIK 1704132.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $290.2m
- Positions: 6 (6 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1704132/000110465926097103/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| Pharvaris N.V. | COM | $165.2m | 57.0% | 4,778,581 |  | Unchanged |
| [CYTOKINETICS INC (CYTK)](/companies/cytk.md) | COM | $60.9m | 21.0% | 714,695 |  | Added +211,400 |
| [Eikon Therapeutics, Inc. (EIKN)](/companies/eikn.md) | COM | $25.4m | 8.7% | 1,943,682 |  | Unchanged |
| [Relay Therapeutics, Inc. (RLAY)](/companies/rlay.md) | COM | $23.4m | 8.1% | 1,250,000 |  | Added +250,000 |
| [Xenon Pharmaceuticals Inc. (XENE)](/companies/xene.md) | COM | $9.7m | 3.3% | 160,000 |  | Unchanged |
| Crinetics Pharmaceuticals, Inc. | COM | $5.6m | 1.9% | 150,000 |  | New +150,000 |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Alector, Inc. (ALEC)](/companies/alec.md) | COM | $0 | 0.0% | 0 |  | Sold out −3,887,200 |
| [Lyell Immunopharma, Inc. (LYEL)](/companies/lyel.md) | COM | $0 | 0.0% | 0 |  | Sold out −800,399 |
| [Maze Therapeutics, Inc. (MAZE)](/companies/maze.md) | COM | $0 | 0.0% | 0 |  | Sold out −156,901 |

Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-097103. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.